"Vidangadi Lauha"用于肥胖的2型糖尿病患者 - 一个开放式随机对照临床试验
Punam Khobarkar1, Jayant Gulhane2, Amit Nakanekar2
1All India Institute of Ayurveda, New Delhi, India.
Journal of Ayurveda and integrative medicine
|January 25, 2024
概括
这项研究发现,Vidangadi Lauha (VL) 和Metformin (MT) 在肥胖的2型糖尿病患者中同样降低了血糖和BMI. 与MT相比,VL在阿育吠陀症状,生活质量和肠道问题上表现出了卓越的改善.
科学领域:
- 艾尔维达是一种阿育韦德.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 与肥胖相关的2型糖尿病呈现出令人担忧的微血管和宏血管并发症.
- 由于糖尿病的复杂发病因,多重向治疗比单一向治疗更受青.
研究的目的:
- 在患有2型糖尿病的肥胖患者中,比较Ayurvedic配方Vidangadi Lauha (VL) 与Metformin (MT) 的疗效.
主要方法:
- 一个开放标签,随机控制的临床研究进行了三个月.
- 参与者接受了VL (5gm两次) 或Metformin (MT) (500mg两次).
主要成果:
- 无论是VL和MT都显著降低了HbA1c和体重指数 (BMI).
- 与MT相比,VL在印度糖尿病 (QOLID) 评分和肠道症状问卷上的生活质量仪表表表现出更大的改善.
- 此外,VL在降低腰比和胆固醇水平方面也显示出更好的结果.
结论:
- 维丹加迪劳哈 (VL) 和甲胺 (MT) 在控制肥胖型2型糖尿病的血糖控制 (HbA1c) 和BMI方面同样有效.
- VL在改善阿育吠陀特异性症状,生活质量和胃肠道健康方面比梅特福明提供了额外的好处.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Diabetes: Symptoms, Diagnosis, and Complications
544
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
544
Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174


